Clinical Trial Detail

NCT ID NCT01646125
Title An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Docetaxel

Luminespib

Pemetrexed Disodium

Age Groups: senior adult

No variant requirements are available.